These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 19249493)

  • 1. Eighteen-year follow-up of a retrospective study of HLA antibody on kidney graft survival.
    Lee PC; Ozawa M; Hung CJ; Lin YJ; Chang SS; Chou TC
    Transplant Proc; 2009; 41(1):121-3. PubMed ID: 19249493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M; Hung CJ; Lin YJ; Chang SS; Chou TC
    Transplant Proc; 2009; 41(1):95-8. PubMed ID: 19249487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA class I antibodies in patients awaiting kidney transplantation and the association with renal graft survival.
    Wu HH; Tien YC; Huang CI; Chiang YJ; Chu SH; Lai PC
    Transplant Proc; 2008 Sep; 40(7):2191-4. PubMed ID: 18790188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA antibodies and soluble CD30 are associated with poor renal graft outcome: updated results of a single-center cross-sectional study.
    Langan LL; D'Orsogna L; Park LP; Hughes TL; Irish A; Luxton G; Witt CS; Christiansen FT
    Clin Transpl; 2006; ():219-25. PubMed ID: 18365380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical significance of human leukocyte antigen antibody development in kidney transplantation.
    Lee PC; Chen YL; Chou TC; Wang WM; Wang JD; Hung CJ; Chang SS; Lin YJ; Chan RH
    Transplant Proc; 2012 Jan; 44(1):264-6. PubMed ID: 22310628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.
    Kaczmarek I; Deutsch MA; Kauke T; Beiras-Fernandez A; Schmoeckel M; Vicol C; Sodian R; Reichart B; Spannagl M; Ueberfuhr P
    Exp Clin Transplant; 2008 Sep; 6(3):229-35. PubMed ID: 18954302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-specific HLA antibodies in chronic renal allograft rejection: a prospective trial with a four-year follow-up.
    Lachmann N; Terasaki PI; Schönemann C
    Clin Transpl; 2006; ():171-99. PubMed ID: 18365377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Good kidney transplant outcome in recipients with presensitization against HLA class II but not HLA class I.
    Süsal C; Opelz G
    Hum Immunol; 2004 Aug; 65(8):810-6. PubMed ID: 15336782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of HLA antibodies and its impact on graft function in a group of kidney transplant recipients: a cross-sectional study.
    Morales-Buenrostro LE; Buzo-Romero JM; de Leo C; López M; Ortiz-Arroyo VM; Pérez-Garrido J; Herrera-Garcia C; Granados J; Alberú J
    Transplant Proc; 2006 Apr; 38(3):899-902. PubMed ID: 16647503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation.
    Hourmant M; Cesbron-Gautier A; Terasaki PI; Mizutani K; Moreau A; Meurette A; Dantal J; Giral M; Blancho G; Cantarovich D; Karam G; Follea G; Soulillou JP; Bignon JD
    J Am Soc Nephrol; 2005 Sep; 16(9):2804-12. PubMed ID: 16014742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss.
    Panigrahi A; Gupta N; Siddiqui JA; Margoob A; Bhowmik D; Guleria S; Mehra NK
    Hum Immunol; 2007 May; 68(5):362-7. PubMed ID: 17462503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of Luminex donor-specific crossmatches: data from 165 renal transplants.
    Billen EV; Christiaans MH; van den Berg-Loonen EM
    Tissue Antigens; 2009 Sep; 74(3):205-12. PubMed ID: 19497037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss.
    Rodríguez LM; París SC; Arbeláez M; Cotes JM; Süsal C; Torres Y; García LF
    Hum Immunol; 2007 Aug; 68(8):652-60. PubMed ID: 17678719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility.
    Castillo-Rama M; Castro MJ; Bernardo I; Meneu-Diaz JC; Elola-Olaso AM; Calleja-Antolin SM; Romo E; Morales P; Moreno E; Paz-Artal E
    Liver Transpl; 2008 Apr; 14(4):554-62. PubMed ID: 18383092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss.
    Lee PC; Zhu L; Terasaki PI; Everly MJ
    Transplantation; 2009 Aug; 88(4):568-74. PubMed ID: 19696641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report.
    Süsal C; Döhler B; Opelz G
    Hum Immunol; 2009 Aug; 70(8):569-73. PubMed ID: 19375472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosensitization to HLA and MICA is an important measure of renal graft outcome.
    Panigrahi A; Siddiqui JA; Rai A; Margoob A; Khaira A; Bhowmik D; Tiwari SC; Guleria S; Mehra NK
    Clin Transpl; 2007; ():211-7. PubMed ID: 18637472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.
    Lachmann N; Terasaki PI; Budde K; Liefeldt L; Kahl A; Reinke P; Pratschke J; Rudolph B; Schmidt D; Salama A; Schönemann C
    Transplantation; 2009 May; 87(10):1505-13. PubMed ID: 19461487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.